Results 221 to 230 of about 19,123,678 (263)

LDL-C target attainment and treatment costs in high-risk and very-high-risk patients with or without bempedoic acid: A Spanish cohort simulation. [PDF]

PLoS One
Cosin-Sales J, Abad-Sazatornil MR, Martín-Conde JA, Alonso Iglesias E, Mostaza Prieto JM.   +4 more
europepmc   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

LDL-C modifies the association between triglycerides and depression identified by threshold scanning in US adults. [PDF]

Sci Rep
Li S, Li J, Xiang F, Huang Q, Xian X, Liu J, Xian Y.   +6 more
europepmc   +1 more source

Gut Enterococcus faecium derived leucic acid mediates the antiobesity effect of dietary fiber

iMeta, EarlyView.
This study identified Enterococcus faecium as a gut bacterium with anti‐obesity activity, which alleviated adipocyte hypertrophy, dyslipidemia, and hepatic steatosis by converting leucine into leucic acid (LEA) to regulate mitochondrial oxidative phosphorylation.
Baifei Hu, Qianru Gao, Junmin Hui, Mengqiong Wang, Haiyan Gao, Kai Li, Junping Zheng, Zhe Dai, Songlin Liu, Hongtao Liu   +9 more
wiley   +1 more source

Prognostic value of combined LDL-C and remnant cholesterol stratification for 24-month major adverse cardiovascular events after primary PCI in patients with STEMI. [PDF]

Front Cardiovasc Med
Xie Q, Wang C, Zhao W, Cai L, Yu C, Pang L.   +5 more
europepmc   +1 more source

TRIM31–LOX‐1 Axis: A Novel Therapeutic Frontier in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis, driven by a vicious cycle of lipid accumulation and chronic inflammation, underlies most cardiovascular diseases. Macrophages exacerbate this process by internalizing oxidized low‐density lipoprotein (oxLDL), forming foam cells, and releasing inflammatory mediators. A recent study published in Circulation identified the TRIM31–
Qian Zhang, Cheng Xue Qin
wiley   +1 more source

LDL-C lowering in patients treated with bempedoic acid in a real-world cohort. [PDF]

Atheroscler Plus
Nelson J, Bloedon L, Lewandowski D, Vaduganathan M, Ajose M, Bonafede M, Sarnes E.   +6 more
europepmc   +1 more source

Metrnl: A Novel Therapeutic Target in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis is a chronic inflammatory vascular disease and the main pathological basis of cardiovascular and cerebrovascular events. Exploration of endogenous protective factors in the disease is beneficial for the establishment of new therapeutic strategies.
Pin Wang, Dao‐Xin Wang, Chao‐Yu Miao
wiley   +1 more source

Distinct phenotype of isolated dizziness stroke: association with cerebellar infarctions and elevated LDL-C. [PDF]

Front Neurol
Zhang B, Liu X, Su X, Chu L, Wang H, Nie L, Yan S.   +6 more
europepmc   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source